CAS 104632-27-1: 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N<sup>6</sup>-propyl-, hydrochloride (1:2), (6R)-
Formula:C10H17N3S·2ClH
InChI:InChI=1S/C10H17N3S.2ClH/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H/t7-;;/m1../s1
InChI key:InChIKey=QMNWXHSYPXQFSK-XCUBXKJBSA-N
SMILES:NC1=NC2=C(C[C@H](NCCC)CC2)S1.Cl
Synonyms:- (R)-4,5,6,7-Tetrahydro-6-(propylamino)-benzothiazole-2-amine dihydrochloride
- SND 919CL2X
- 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (6R)-
- 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (R)-
- 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, hydrochloride (1:2), (6R)-
Sort by
Found 10 products.
Pramipexole impurity D CRS
CAS:Pramipexole impurity D CRSFormula:C10H19Cl2N3SColor and Shape:Powder.Molecular weight:284.249Pramipexole Related Compound D
CAS:Controlled ProductPramipexole-related compound D is a dopamine agonist with clinical effects similar to those of pramipexole. It can be used to treat Parkinson's disease and restless leg syndrome. Studies have shown that it is a potent inhibitor of dopamine receptor activity and the termination of dopaminergic neurotransmission. Pramipexole-related compound D has been shown to enhance dopamine receptor-mediated, receptor-mediated, and extracellular responses in animals. In addition, this drug has been found to decrease locomotor activity in rats by blocking the activation of the d2 receptor.Formula:C10H17N3S·2HClPurity:Min. 95%Molecular weight:284.25 g/molPramipexole EP Impurity D DiHCl (Pramipexole USP Related Compound D)
CAS:Formula:C10H17N3S·2HClColor and Shape:White To Off-White SolidMolecular weight:211.33 2 36.46(R)-Pramipexole Dihydrochloride
CAS:Controlled ProductImpurity Pramipexole EP Impurity D; Pramipexole BP Impurity D; Pramipexole USP Related Compound D Applications (R)-Pramipexole Dihydrochloride (Pramipexole EP Impurity D; Pramipexole BP Impurity D; Pramipexole USP Related Compound D) is the opposite enantiomer of Pramipexole (P700755), a dopamine-D2-receptor agonist. Dexpramipexole is a low-molecular-weight, water-soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics. References Mierau, J., et al.: J. Med. Chem., 30, 494 (1987), Schilling, J.C., et al.: Clin. Pharmacol. Ther., 51, 541 (1992), Kieburtz, K., et al.: J. Am. Med. Assoc., 278, 125 (1997)Formula:C10H17N3S·2ClHColor and Shape:NeatMolecular weight:284.25Dexpramipexole dihydrochloride
CAS:Dexpramipexole dihydrochloride (KNS-760704 dihydrochloride) ((R)-Pramipexole dihydrochloride) is a neuroprotective agent and is a weak non-ergoline dopamineFormula:C10H19Cl2N3SPurity:99.75% - 99.88%Color and Shape:SolidMolecular weight:284.25Ref: TM-T11011
5mg52.00€10mg79.00€25mg153.00€50mg250.00€100mg378.00€200mg552.00€1mL*10mM (DMSO)52.00€(S)-Pramipexole-d7 Dihydrochloride
CAS:Controlled ProductApplications (S)-Pramipexole-d7 dihydrochloride is the labelled hydrochloride salt analogue of (S)-Pramipexole (P700750), a dopamine-D2-receptor agonist which is used to treat early-stage Parkinson's disease (PD) and restless legs syndrome (RLS). References Mierau, J., et al.: J. Med. Chem., 30, 494 (1987), Schilling, J.C., et al.: Clin. Pharmacol. Ther., 51, 541 (1992), Kieburtz, K., et al.: J. Am. Med. Assoc., 278, 125 (1997)Formula:C10H10D7N3S• 2(HCl)Color and Shape:NeatMolecular weight:218.37 + 2(36.46)Dexpramipexole dihydrochloride
CAS:Dexpramipexole dihydrochloridePurity:≥98%Molecular weight:284.25g/molPramipexole Related Compound D ((R)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride)
CAS:Compounds containing a benzothiazole ring-system (whethFormula:C10H17N3S·2HClColor and Shape:Off-White PowderMolecular weight:283.06767PRAMIPEXOLE HYDROCHLORIDE
CAS:Formula:C10H19Cl2N3SPurity:%Color and Shape:SolidMolecular weight:284.249
